NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
XPO Logistics, Inc. (NYSE: XPO) Class Period: February 26, 2014 - December 12, 2018 Lead Plaintiff Deadline: February 12, 2019 Join the action: https://www.zlk.com/pslra-1/xpo-logistics-inc...orm?wire=3
The lawsuit alleges: XPO Logistics, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) XPO’s highly touted aggressive M&A strategy had yielded only minimal returns to the Company; (ii) XPO was utilizing improper accounting practices to mask its true financial condition, including, inter alia, under-reporting of bad debts and aggressive amortization assumptions; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
To learn more about the XPO Logistics, Inc. class action contact jlevi@levikorsinsky.com .
Immunomedics, Inc. (NASDAQ: IMMU) Class Period: February 8, 2018 - January 18, 2019 Lead Plaintiff Deadline: February 25, 2019 Join the action: https://www.zlk.com/pslra-1/immunomedics-inc-...orm?wire=3
The lawsuit alleges: Immunomedics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Immunomedics’ Morris Plains, New Jersey drug substance manufacturing facility was not in compliance with FDA requirements; (ii) the Company’s Quality Control Unit did not possess the authority to investigate and correct critical FDA violations occurring at the Morris Plains, New Jersey facility; (iii) the Company suffered a February 2018 data integrity breach at the Morris Plains, New Jersey facility which, among other issues, included the backdating records and manipulation of bioburden samples; (iv) the Company’s Chemistry, Manufacturing and Control data submitted in connection with its BLA for sacituzumab govitecan was insufficient to support FDA approval; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times
To learn more about the Immunomedics, Inc. class action contact jlevi@levikorsinsky.com .
DXC Technology Company (NYSE: DXC) Class Period: February 8, 2018 - November 6, 2018 Lead Plaintiff Deadline: February 25, 2019 Join the action: https://www.zlk.com/pslra-1/dxc-technology-co...orm?wire=3
The lawsuit alleges: DXC Technology Company made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (a) the Company had changed or planned to change the operations of its sales teams, deploying generalized sales teams as opposed to the specialized teams that were better capable of delivering specialized services to its clients; (b) the Company’s workforce optimization strategy of sharply reducing staff while reducing costs was resulting in a shortage of sales personnel who could execute on demand for services, thereby risking and ultimately losing sales and revenue opportunities; (c) in light of the above, the Company’s revenue and financial performance guidance for the fiscal year 2019 and its reaffirmation of the guidance during the Class Period was without a reasonable basis.
To learn more about the DXC Technology Company class action contact jlevi@levikorsinsky.com .
ProShares Short VIX Short-Term Futures (NYSEArca: SVXY) Class Period: Investors in ProShares Short VIX Short-Term Futures ETF pursuant to the May 15, 2017 Registration Statement and/or between May 15, 2017 and February 5, 2018 Lead Plaintiff Deadline: April 1, 2019 Join the action: https://www.zlk.com/pslra-1/proshares-short-v...orm?wire=3
The lawsuit alleges: ProShares Short VIX Short-Term Futures made materially false and/or misleading statements and/or failed to disclose that: According to the complaint in the Registration Statement and during the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information regarding the risks of investing in the Fund. Specifically, the Registration Statement failed to disclose that the Fund was threatened with catastrophic losses as a result of the Fund’s flawed design and the low-volatility environment and acute liquidity risks that existed during the Class Period. In addition, during the Class Period defendants made similar false and misleading statements in numerous financial reports and draft prospectuses and registration statements filed with the SEC.
To learn more about the ProShares Short VIX Short-Term Futures class action contact jlevi@levikorsinsky.com .
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 55 Broadway, 10th Floor New York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
